Boston Scientific Corporation (NYSE: BSX) announces it has entered into a definitive agreement to acquire SoniVie Ltd., a privately held medical device company that has developed the TIVUS™ Intravascular Ultrasound System. An investigational technology, the TIVUS system is designed to denervate nerves surrounding blood vessels to treat a variety of hypertensive disorders, including renal artery denervation (RDN) for hypertension. As a strategic investor in SoniVie, Boston Scientific currently holds an equity stake of approximately 10 percent. Therefore, the transaction consists of an upfront payment of approximately $360 million for the 90 percent stake not yet owned and up to $180 million upon achievement of a regulatory milestone.
Read the full article: Boston Scientific Announces Agreement to Acquire SoniVie Ltd. //
Source: https://www.prnewswire.com/news-releases/boston-scientific-announces-agreement-to-acquire-sonivie-ltd-302389586.html